|
Differentially Methylated Promoters: APBA1, APC, CADM1, CDH1, CDH13, CDKN1C, CDKN2A, CDKN2B, CXCL12, CYP1B1, DLC1, FHIT, MGMT, MLH1, MTHFR, OPCML, PRDM2, RASSF1, RASSF2, SFRP1, TCF21.
Metastatic Potential: ANXA5, DUSP6, ERBB3, HGF, HMMR, IRF4, LCK, MET, MMD, NF1, STAT1, STAT2.
Differentially Expressed Genes in Adenocarcinoma (AC) Versus Squamous Cell Carcinoma (SCC):
Higher in AC than in SCC: CLCA2, DSG3, KRT5, KRT14, SPRR1A.
Higher in SCC than in AC: AGR2, LGSN, NKX2-1, SFTA3, SPINK1.
Up-Regulated in Lung Cancer: CEACAM5, COL11A1, CP, CXCL13, GREM1, MKI67, MMP1, MMP12, SPINK1, SPP1, TOP2A, TOX3.
Down-Regulated in Lung Cancer: AGER, CA4, CLDN18, CLIC5, FABP4, GPM6A, SCGB1A1, SFTPC, SOSTDC1, WIF1.
PI3K/AKT Signaling: AKT1, BCL2, CDH1, CDKN2A, EGFR, NFKB1, TP53, VEGFA.
Apoptosis: ANXA5, APC, BCL2, BIRC5, BRAF, CADM1, CDH1, CDH13, CDKN2A, DLC1, EGFR, ERBB2, ERBB3, HGF, HRAS, KRAS, LCK, MLH1, MMP9, NF1, NFKB1, PTGS2, SFRP1, STAT1, TERT, TGFB1, TNF, TOP2A, TP53, VEGFA.
Cell Cycle Regulation: APC, BCL2, BIRC5, CDKN1C, CDKN2A, CDKN2B, EGFR, PTGS2, RB1, TGFB1, TNF, TP53.
Immune Response: BCL2, CADM1, CSF3, CXCL12, CXCL13, IRF4, LCK, MLH1, MMD, NFKB1, PAX5, STAT1, STAT2, TGFB1, TNF, TP53, VEGFA.
Extracellular Matrix & Cell Adhesion: CADM1, CDH1, CDH13, CEACAM6, CLDN18, COL11A1, DSG3, GPM6A, HMMR, KRT14, KRT5, MET, MMP1, MMP12, MMP9, SFTA3, SFTPC.
|